<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BELEODAQ- belinostatÂ injection, powder, lyophilized, for solutionÂ </strong><br>Spectrum Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.<br><br>BELEODAQÂ® (belinostat) for injection, for intravenous administration<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Beleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. <span class="Italics"><a href="#i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f">(1)</a></span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Recommended dosage of Beleodaq is 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes by intravenous infusion once daily on days 1-5 of a 21-day cycle. Cycles can be repeated until disease progression or unacceptable toxicity. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac">2.1</a></span>)</dd>
<dt>â€¢</dt>
<dd>Treatment discontinuation or interruption with or without dosage reductions by 25% may be needed to manage adverse reactions. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a></span>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">For injection: 500 mg, lyophilized powder in single-use vial for reconstitution (<span class="Italics"><a href="#i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282">3</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<span class="Italics"><a href="#i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8">4</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>: Monitor blood counts and modify dosage for hematologic toxicities. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>, <a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a></span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: Serious and fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>). (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a></span>)</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities. Monitor liver function tests and omit or modify dosage for hepatic toxicities. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>, <a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a></span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span>: Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions. (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</a></span>)</dd>
<dt>â€¢</dt>
<dd>Embryo-fetal toxicity: Beleodaq may cause fetal harm when administered to a pregnant woman. Advise women of potential harm to the fetus and to avoid pregnancy while receiving Beleodaq. (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a></span>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;25%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<span class="Italics"><a href="#i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0">6</a></span>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Spectrum Pharmaceuticals, Inc. at 1-888-292-9617 or FDA at 1-800-FDA-1088</span>Â <span class="Bold">or</span>Â <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Italics">Nursing Mothers: </span> Women should be advised against breastfeeding while being treated with Beleodaq. (<span class="Italics"><a href="#i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574">8.3</a></span>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Modification for Hematologic and Non-Hematologic Toxicities</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with Reduced UGT1A1 Activity</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation and Administration Precautions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Reconstitution and Infusion Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hematologic Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 UGT1A1 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Warfarin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Beleodaq is indicated for the treatment of patients with relapsed or refractory peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (PTCL).</p>
<p>This indication is approved under accelerated approval based on tumor response rate and duration of response <span class="Italics">[see Clinical Studies (<a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a>)].</span> An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended dosage of Beleodaq is 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes by intravenous infusion once daily on Days 1-5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or unacceptable toxicity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Modification for Hematologic and Non-Hematologic Toxicities</h2>
<p class="First">Table 1 displays the recommended Beleodaq dosage modifications for hematologic and non-hematologic toxicities. Base dosage adjustments for <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> on platelet and absolute neutrophil nadir (lowest value) counts in the preceding cycle of therapy.</p>
<dl>
<dt>â€¢</dt>
<dd>Absolute neutrophil count (ANC) should be greater than or equal to 1.0 x 10<span class="Sup">9</span>/L and the platelet count should be greater than or equal to 50 x 10<span class="Sup">9</span>/L prior to the start of each cycle and prior to resuming treatment following toxicity. Resume subsequent treatment with Beleodaq according to the guidelines described in Table 1 below. Discontinue Beleodaq in patients who have recurrent ANC nadirs less than 0.5 x 10<span class="Sup">9</span>/L and/or recurrent platelet count nadirs less than 25 x 10<span class="Sup">9</span>/L after two dosage reductions.</dd>
<dt>â€¢</dt>
<dd>Other toxicities must be NCI-CTCAE Grade 2 or less prior to re-treatment.</dd>
</dl>
<p>Monitor complete blood counts at baseline and weekly. Perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle. </p>
<table width="100%">
<caption><span>Table 1: Dosage Modifications for Hematologic and Non-Hematologic Toxicities</span></caption>
<col width="56%">
<col width="44%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, only dose modify if the duration is greater than 7 days with supportive management</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dosage Modification</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First"><span class="Bold">Dosage Modifications due to Hematologic Toxicities</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Platelet count â‰¥ 25 x 10<span class="Sup">9</span>/L and nadir ANC â‰¥ 0.5 x 10<span class="Sup">9</span>/L</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">No Change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Nadir ANC &lt; 0.5 x 10<span class="Sup">9</span>/L (any platelet count)</p></td>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="First">Decrease dosage by 25% (750 mg/m<span class="Sup">2</span>)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Platelet count &lt; 25 x 10<span class="Sup">9</span>/L (any nadir ANC)</p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First"><span class="Bold">Dosage Modifications due to Non-Hematologic Toxicities</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Any CTCAE Grade 3 or 4 adverse reaction<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Decrease dosage by 25% (750 mg/m<span class="Sup">2</span>)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Recurrence of CTCAE Grade 3 or 4 adverse reaction after two dosage reductions</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Discontinue Beleodaq</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_66ef38bd-654c-425e-8932-5a423a723d2f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with Reduced UGT1A1 Activity</h2>
<p class="First">Reduce the starting dose of Beleodaq to 750 mg/m<span class="Sup">2</span> in patients known to be homozygous for the UGT1A1*28 allele <span class="Italics">[see Clinical Pharmacology (<a href="#ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c">12.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_9a204218-9064-4333-9d6d-52c5b5836041"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation and Administration Precautions</h2>
<p class="First">As with other potentially cytotoxic anticancer agents, exercise care in the handling and preparation of solutions prepared with Beleodaq.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_509787c6-fc67-4d60-851e-574992f9a805"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Reconstitution and Infusion Instructions</h2>
<dl>
<dt>a)</dt>
<dd>Aseptically reconstitute each vial of Beleodaq by adding 9 mL of Sterile Water for injection, USP, into the Beleodaq vial with a suitable syringe to achieve a concentration of 50 mg of belinostat per mL. Swirl the contents of the vial until there are no visible particles in the resulting solution. The reconstituted product may be stored for up to 12 hours at ambient temperature (15-25Â°C; 59-77Â°F).</dd>
<dt>b)</dt>
<dd>Aseptically withdraw the volume needed for the required dosage (based on the 50 mg/mL concentration and the patientâ€™s BSA [m<span class="Sup">2</span>]) and transfer to an infusion bag containing 250 mL of 0.9 % Sodium Chloride injection. The infusion bag with drug solution may be stored at ambient room temperature (15-25Â°C; 59-77Â°F) for up to 36 hours including infusion time.</dd>
<dt>c)</dt>
<dd>Visually inspect the solution for particulate matter. Do not use if cloudiness or particulates are observed.</dd>
<dt>d)</dt>
<dd>Connect the infusion bag containing drug solution to an infusion set with a 0.22 Âµm in-line filter for administration.</dd>
<dt>e)</dt>
<dd>Infuse intravenously over 30 minutes. If infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or other symptoms potentially attributable to the infusion occur, the infusion time may be extended to 45 minutes.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">For injection: 500 mg, lyophilized powder in single-use vial for reconstitution</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_4f5d1822-ea0a-4087-8d1a-b3de996531f7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hematologic Toxicity</h2>
<p class="First">Beleodaq can cause <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; monitor blood counts weekly during treatment, and modify dosage as necessaryÂ <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a></span>) and <span class="Italics">Adverse Reactions</span><span class="Italics">(<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, have occurred with Beleodaq. Do not administer Beleodaq to patients with an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients with a history of extensive or intensive chemotherapy may be at higher risk of life threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatotoxicity</h2>
<p class="First">Beleodaq can cause fatal hepatotoxicity and liver function test abnormalitiesÂ <span class="Italics">[see Adverse Reactions</span> (<span class="Italics"><a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue Beleodaq based on the severity of the hepatic toxicity<span class="Italics">[see Dosage and Administration (</span><span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> has occurred in Beleodaq-treated patients in the clinical trial of patients with relapsed or refractory PTCLÂ <span class="Italics">[see</span>Â <span class="Italics">Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>. Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautionsÂ <span class="Italics">[see</span>Â <span class="Italics">Adverse Reactions</span> (<span class="Italics"><a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a></span>)<span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur with BeleodaqÂ <span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)] </span>and may require the use of antiemetic and antidiarrheal medications.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Embryo-fetal Toxicity</h2>
<p class="First">Beleodaq can cause fetal harm when administered to a pregnant woman. Beleodaq may cause <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cellsÂ <span class="Italics">[see Nonclinical Toxicology</span> (<span class="Italics"><a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</a></span>)<span class="Italics">]</span>. Women of childbearing potential should be advised to avoid pregnancy while receiving Beleodaq. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of potential hazard to the fetusÂ <span class="Italics">[see Use in Specific Populations</span> (<span class="Italics"><a href="#i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9">8.1</a></span>)<span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described in more detail in other sections of the prescribing information.</p>
<dl>
<dt>â€¢</dt>
<dd>Hematologic ToxicityÂ <span class="Italics">[see Warnings and Precautions</span> (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span><span class="Italics"> [see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</a>)]</span>
</dd>
</dl>
<p>The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Beleodaq may not reflect the rates observed in practice.</p>
<p><span class="Underline">Adverse Reactions in Patients with Peripheral T-Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<p>The safety of Beleodaq was evaluated in 129 patients with relapsed or refractory PTCL in the single arm clinical trial in which patients were administered Beleodaq at a dosage of 1,000 mg/m2 administered over 30 minutes by IV infusion once daily on Days 1-5 of a 21-day cycle <span class="Italics">[see Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>. The median duration of treatment was 2 cycles (range 1 â€“ 33 cycles).</p>
<p>Table 2 summarizes the adverse reactions regardless of causality from the trial in patients with relapsed or refractory PTCL.</p>
<table width="98.58%">
<caption><span>Table 2: Adverse Reactions Occurring in â‰¥ 10% of Patients by Preferred Term and Severity in Patients with Relapsed or Refractory PTCL (NCI-CTC Grade 1-4)</span></caption>
<col width="52%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">MedDRA Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle">
<p class="First"><span class="Bold">Percentage of Patients (%)</span></p>
<p><span class="Bold">(N=129)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Grade 3 or 4</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">All Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">97</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">61</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increased Blood Lactate Dehydrogenase </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Infusion Site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Prolonged QT </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Note: Adverse reactions are listed by order of incidence in the â€œAll Gradesâ€? category first, then by incidence in â€œthe Grade 3 or 4â€? category; MedDRA = Medical Dictionary for Regulatory Activities; Severity measured by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0</p>
<p><span class="Underline">Serious Adverse Reactions</span></p>
<p>Sixty-one patients (47.3%) experienced serious adverse reactions while taking Beleodaq or within 30 days after their last dose of Beleodaq. The most common serious adverse reactions (&gt; 2%) were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and multi-organ failure. One treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> was reported in the trial.</p>
<p>One patient with baseline <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and bulky disease experienced Grade 4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> during the first cycle of treatment and died due to multi-organ failure. A treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> was reported in another monotherapy clinical trial with Beleodaq. ECG analysis did not identify QTc prolongation.</p>
<p><span class="Underline">Discontinuations due to Adverse Reactions</span></p>
<p>Twenty-five patients (19.4%) discontinued treatment with Beleodaq due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment included <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and multi-organ failure.</p>
<p><span class="Underline">Dosage Modifications due to Adverse Reactions</span></p>
<p>In the trial, dosage adjustments due to adverse reactions occurred in 12% of Beleodaq-treated patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_456775d3-18a0-4b58-8d34-377cd2f5e7ee"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_a497571b-109d-4617-847a-56cac2dfd851"></a><a name="section-7.1"></a><p></p>
<h2>7.1 UGT1A1 Inhibitors</h2>
<p class="First">Belinostat is primarily metabolized by UGT1A1. Avoid concomitant administration of Beleodaq with strong inhibitors of UGT1A1 <span class="Italics">[see Clinical Pharmacology</span> (<span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a></span>)<span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_e4ace375-7ddc-40c0-9140-3c4e47ae7fa7"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Warfarin</h2>
<p class="First">Co-administration of Beleodaq and warfarin resulted in no clinically relevant increase in plasma exposure of either R-warfarin or S-warfarin that would require a dose adjustment <span class="Italics">[see Clinical Pharmacology (</span><span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3)</a></span><span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a><a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">)</a></span>].</p>
<p><span class="Italics">Risk Summary</span></p>
<p>Beleodaq may cause <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and/or embryo-fetal lethality because it is a genotoxic drug and targets actively dividing cells <span class="Italics">[see Nonclinical Toxicology (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</a>)]</span>. Women should avoid pregnancy while receiving Beleodaq. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of potential hazard to the fetus. </p>
<p><span class="Italics">Animal Data</span></p>
<p>No reproductive and developmental animal toxicology studies have been conducted with belinostat.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether belinostat is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Beleodaq, a decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fc875ec0-c1a4-4690-b737-865272ba9472"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pediatric patients were not included in clinical trials. The safety and effectiveness of Beleodaq in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_c27428be-56cb-4540-844a-37578fdfd2b2"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the single-arm trial, 48% of patients (n = 62) were â‰¥ 65 years of age and 10% of patients (n=13) were â‰¥ 75 years of age <span class="Italics">[see Clinical Studies (<a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a>)]</span>. The median age of the trial population was 63 years. Patients â‰¥ 65 years of age had a higher response rate to Beleodaq treatment than patients &lt; 65 years of age (36% versus 16%) while no meaningful differences in response rate were observed between patients â‰¥ 75 years of age and those &lt; 75 years of age. No clinically meaningful differences in serious adverse reactions were observed in patients based on age (&lt; 65 years compared with â‰¥ 65 years or &lt; 75 years of age compared with â‰¥ 75 years of age).</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_duplicate_id_8c25fb28-cfbd-489b-92f1-7a46d506ee2f"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Belinostat is metabolized in the liver and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is expected to increase exposure to belinostat. Patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt;1.5 x upper limit of normal (ULN)) were excluded from clinical trials. </p>
<p>There is insufficient data to recommend a dose of Beleodaq in patients with moderate and severe hepatic impairmentÂ <span class="Italics">[seeÂ Clinical PharmacologyÂ (<a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_duplicate_id_9f086d02-a930-4b85-ad93-77a6aeec7a23"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Approximately 40% of the belinostat dose is excreted renally, primarily as metabolites. Belinostat exposure is not altered in patients with Creatinine Clearance (CLcr) &gt; 39 mL/min. There is insufficient data to recommend a dose of Beleodaq in patients with CLcr â‰¤ 39 mL/min. <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_24dd5315-f21c-484c-9b2a-547f9f42ac9a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, general supportive measures should be instituted as deemed necessary by the treating physician. The elimination half-life of belinostat is 1.1 hoursÂ <span class="Italics">[see Clinical Pharmacology</span> (<span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3)</a></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d8e21c3f-5354-456b-901e-210f62270c6b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Beleodaq is a histone deacetylase inhibitor with a sulfonamide-hydroxamide structure. The chemical name of belinostat is (2E)-<span class="Italics">N</span>-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide. The structural formula is as follows:</p>
<div class="Figure">
<a name="id650"></a><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-01.jpg">
</div>
<p>The molecular formula is C<span class="Sub">15</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">4</span>S and the molecular weight is 318.35 g/mol.</p>
<p>Belinostat is a white to off-white powder. It is slightly soluble in distilled water (0.14 mg/mL) and polyethylene glycol 400 (about 1.5 mg/mL), and is freely soluble in ethanol (&gt; 200 mg/mL). The pKa values are 7.87 and 8.71 by potentiometry and 7.86 and 8.59 by UV.</p>
<p>Beleodaq (belinostat) for injection is supplied as a sterile lyophilized yellow powder containing 500 mg belinostat as the active ingredient. Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. The drug product is supplied in a single-use 30 mL clear glass vial with a coated stopper and aluminum crimp seal with â€œflip-offâ€? cap. Beleodaq is intended for intravenous administration after reconstitution with 9 mL Sterile Water for injection, and the reconstituted solution is further diluted with 250 mL of sterile 0.9% Sodium Chloride injection prior to infusion <span class="Italics">[see Dosage and Administration (</span><span class="Italics"><a href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476">2)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3db12f71-0cfd-48c9-a69f-ff934e1a006f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_8e6ba92d-e3d3-4963-939c-29b326bbd4b3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. <span class="Italics">In vitro</span>, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (&lt;250 nM).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9a3135c6-b8ac-4597-97ba-48523e9a274e"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Cardiac Electrophysiology</span></p>
<p>Multiple clinical trials have been conducted with Beleodaq, in many of which ECG data were collected and analyzed by a central laboratory. Analysis of clinical ECG and belinostat plasma concentration data demonstrated no meaningful effect of Beleodaq on cardiac repolarization. None of the trials showed any clinically relevant changes caused by Beleodaq on heart rate, PR duration or QRS duration as measures of autonomic state, atrio-ventricular conduction or depolarization; there were no cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic characteristics of belinostat were analyzed from pooled data from phase 1/2 clinical studies that used doses of belinostat ranging from 150 to 1200 mg/m<span class="Sup">2</span>. The total mean plasma clearance and elimination half-life were 1240 mL/min and 1.1 hours, respectively. The total clearance approximates average hepatic blood flow (1500 mL/min), suggesting high hepatic extraction (clearance being flow dependent).</p>
<p><span class="Underline">Distribution</span></p>
<p>The mean belinostat volume of distribution approaches total body water, indicating that belinostat has limited body tissue distribution. <span class="Italics">In vitro</span> plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Belinostat is primarily metabolized by hepatic UGT1A1. Strong UGT1A1 inhibitors are expected to increase exposure to belinostat. Belinostat also undergoes hepatic metabolism by CYP2A6, CYP2C9, and CYP3A4 enzymes to form belinostat amide and belinostat acid. The enzymes responsible for the formation of methyl belinostat and 3-(anilinosulfonyl)-benzenecarboxylic acid, (3-ASBA) are not known.</p>
<p><span class="Underline">Excretion</span></p>
<p>Belinostat is eliminated predominantly through metabolism with less than 2% of the dose recovered unchanged in urine. All major human metabolites (methyl belinostat, belinostat amide, belinostat acid, belinostat glucuronide, and 3-ASBA) are generally excreted in urine within the first 24 hours after dose administration. Metabolites 3-ASBA and belinostat glucuronide represented the highest fractions of the belinostat dose excreted in urine (4.61% and 30.5%, respectively).</p>
<p><span class="Underline">Drug-Drug Interactions</span></p>
<p>In vitro studies showed belinostat and its metabolites (including belinostat glucuronide, belinostat amide, methyl belinostat) inhibited metabolic activities of CYP2C8 and CYP2C9. Other metabolites (3-ASBA and belinostat acid) inhibited CYP2C8. </p>
<p>In cancer patients, co-administration of Beleodaq (1,000 mg/m<span class="Sup">2</span>) and warfarin (5 mg), a known CYP2C9 substrate, did not increase the AUC or C<span class="Sub">max</span> of either R- or S-warfarin. </p>
<p>Belinostat is likely a glycoprotein (P-gp) substrate but is unlikely to inhibit P-gp.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c"></a><a name="section-11.4"></a><p></p>
<h2>12.5 Pharmacogenomics</h2>
<p class="First">UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 20% of the black population, 10% of the white population, and 2% of the Asian population are homozygous for the UGT1A1*28 allele. Additional reduced function alleles may be more prevalent in specific populations.</p>
<p>Because belinostat is primarily (80 -90%) metabolized by UGT1A1, the clearance of belinostat could be decreased in patients with reduced UGT1A1 activity (e.g., patients with UGT1A1*28 allele). Reduce the starting dose of Beleodaq to 750 mg/m<span class="Sup">2</span> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_2e570443-2e43-4d3d-a022-36529932ec42"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been performed with belinostat.</p>
<p>Belinostat was genotoxic in a bacterial reverse mutation test (Ames assay), an in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell mutagenesis assay, and an in vivo rat micronucleus assay. </p>
<p>Beleodaq may impair male fertility. Fertility studies using belinostat were not conducted. However, belinostat effects on male reproductive organs observed during the 24-week repeat-dose dog toxicology study included reduced organ weights of the testes/epididymides that correlated with a delay in testicular maturation</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Underline">Relapsed or Refractory Peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (PTCL)</span></p>
<p>In an open-label, single-arm, non-randomized international trial conducted at 62 centers, 129Â patients with relapsed or refractory PTCL were treated with Beleodaq 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes via IV infusion once daily on Days 1-5 of a 21-day cycle. There were 120 patients who had histologically confirmed PTCL by central review evaluable for efficacy. Patients were treated with repeat cycles every three weeks until disease progression or unacceptable toxicity.</p>
<p>The primary efficacy endpoint was response rate (complete response and partial response) as assessed by an independent review committee (IRC) using the International Workshop Criteria (IWC) (Cheson 2007). The key secondary efficacy endpoint was duration of response. Response assessments were evaluated every 6 weeks for the first 12 months and then every 12 weeks until 2 years from the start of study treatment. Duration of response was measured from the first day of documented response to disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Response and progression of disease were evaluated by the IRC using the IWC.</p>
<p>Table 3 summarizes the baseline demographic and disease characteristics of the study population, who were evaluable for efficacy.</p>
<a name="_RefID991E21B9E3224CD4AB1EBFB4881FA21E"></a><table width="100%">
<caption><span>Table 3 Baseline Patient Characteristics (PTCL Population)</span></caption>
<col width="70%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Characteristics</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Evaluable Patients</span></p>
<p><span class="Bold">(N=120)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Age (years)</p>
<dl>
<dt>Â </dt>
<dd>	Median (range)</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">64.0 (29-81)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Sex, %</p>
<dl>
<dt>Â </dt>
<dd>	Male</dd>
<dt>Â </dt>
<dd>	Female</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">52</p>
<p>48</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Race, %</p>
<dl>
<dt>Â </dt>
<dd>White</dd>
<dt>Â </dt>
<dd>Black</dd>
<dt>Â </dt>
<dd>Asian</dd>
<dt>Â </dt>
<dd>Latin</dd>
<dt>Â </dt>
<dd>Other</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">88</p>
<p>6</p>
<p>3</p>
<p>3</p>
<p>2</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">PTCL Subtype Based on Central Diagnosis, %</p>
<dl>
<dt>Â </dt>
<dd>	PTCL Unspecified (NOS)</dd>
<dt>Â </dt>
<dd>	Angioimmunoblastic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (AITL)</dd>
<dt>Â </dt>
<dd>	ALK-1 negative anaplastic large cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (ALCL)</dd>
<dt>Â </dt>
<dd>	Other</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">64</p>
<p>18</p>
<p>11</p>
<p>7</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Baseline Platelet Count, %</p>
<dl>
<dt>Â </dt>
<dd>	â‰¥100,000/Î¼L</dd>
<dt>Â </dt>
<dd>	&lt;100,000/Î¼L</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">83</p>
<p>17</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">ECOG Performance Status, %</p>
<dl>
<dt>Â </dt>
<dd>	0</dd>
<dt>Â </dt>
<dd>	1</dd>
<dt>Â </dt>
<dd>	2</dd>
<dt>Â </dt>
<dd>3</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"></p>
<p>34</p>
<p>43</p>
<p>22</p>
<p>1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Median time (months) from Initial PTCL Diagnosis (Range)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12.0 (2.6 â€“ 266.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Median Number of Prior Systemic Therapies (Range)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.0 (1-8)</p></td>
</tr>
</tbody>
</table>
<p>In all evaluable patients (N = 120) treated with Beleodaq, the overall response rate per central review using IWC was 25.8% (n = 31) (Table 4) with rates of 23.4% for PTCL, NOS and 45.5% for AITL, the two largest subtypes enrolled. </p>
<a name="_RefID6F802A4E4EF345BDB8C7891823F5598D"></a><table cellpadding="3pt" width="541.5pt">
<caption><span>Table 4: Response Analysis per Central Assessment Using IWC in Patients with Relapsed or Refractory PTCL</span></caption>
<col width="52%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Evaluable Patients<br>(N=120)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold"> Response Rate</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">n (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">(95% CI)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>CR+PR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31 (25.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18.3-34.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>CR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13 (10.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9-17.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>PR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18 (15.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.1 â€“ 22.7</p></td>
</tr>
</tbody>
</table>
<p>CI=confidence interval, CR=complete response, PR=partial response</p>
<p>The median duration of response based on the first date of response to disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 8.4 months (95% CI: 4.5 â€“ 29.4). Of the responders, the median time to response was 5.6 weeks (range 4.3 - 50.4 weeks). Nine patients (7.5%) were able to proceed to a stem cell transplant after treatment with Beleodaq.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_60003015-7603-4806-bdf0-b0e4ba2e15cd"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>OSHA Hazardous Drugs. <span class="Italics">OSHA</span>. [Accessed on 14 May 2014, from <span class="Italics"><a href="http://www.osha.gov/SLTC/hazardousdrugs/index.html">http://www.osha.gov/SLTC/hazardousdrugs/index.html</a></span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5e08debb-9ee1-4da3-a2f7-7953e5276de4"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">16.1 How Supplied</span></p>
<p>Beleodaq (belinostat) for injection is supplied in single vial cartons; each 30 mL clear vial contains sterile, lyophilized powder equivalent to 500 mg belinostat.</p>
<p>NDC 68152-108-09<span class="Bold">: </span>Individual carton of Beleodaq 30 mL single-use vial containing 500 mg belinostat.</p>
<p><span class="Bold">16.2 Storage and Handling</span></p>
<p>Store Beleodaq (belinostat) for injection at room temperature 20Â°C  to 25Â°C (68Â°C  to 77Â°F). Excursions are permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F). Retain in original package until use. [see USP Controlled Room Temperature]. </p>
<p>Beleodaq is a cytotoxic drug. Follow special handling and disposal procedures <span class="Italics">[see References (<a href="#i4i_references_id_60003015-7603-4806-bdf0-b0e4ba2e15cd">15</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_9fb597bb-e1a3-4e33-ab47-f9285b5029f2"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians should discuss the FDA approved Patient Information Leaflet with patients prior to treatment with Beleodaq. Instruct patients to read the Patient Information Leaflet carefully.</p>
<p>Advise the patient or the caregiver to read the FDA-approved patient labeling (Patient Information).</p>
<p>Advise patients or their caregivers:</p>
<dl>
<dt>â€¢</dt>
<dd>To report symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> so that appropriate antiemetic and antidiarrheal medications can be administered <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>To report any symptoms of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see Warnings and Precautions (</span><a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a><span class="Italics">)]</span>.</dd>
<dt>â€¢</dt>
<dd>To immediately report symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>) <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a>) </span>and<span class="Italics"> Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>Of the potential risk to the fetus and for women to avoid pregnancy while receiving Beleodaq <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>To understand the importance of monitoring liver function test abnormalities and to immediately report potential symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>) </span>and<span class="Italics"> Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a>)].</span>
</dd>
</dl>
<p>Manufactured for: </p>
<p>Spectrum Pharmaceuticals, Inc.</p>
<p>Irvine, CA 92618</p>
<p>Beleodaq is a registered trademark of Spectrum Pharmaceuticals, Inc. All rights are reserved.</p>
<p>U.S. Patent: 6,888,027</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_87ad9416-0663-4f1b-80c3-ff7b2368b135"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">BELEODAQ<span class="Sup">Â®</span></span>(BÄ“-lÄ“o-dak)</p>
<p>(belinostat) for injection, for intravenous use</p>
<p>Read this Patient Information before you receive treatment with Beleodaq and each time you receive Beleodaq. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is Beleodaq?</span></p>
<p>Beleodaq is a prescription medicine used to treat people with a type of cancer called peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (PTCL) that comes back or does not respond to cancer treatment. </p>
<p>It is not known if Beleodaq is safe and effective in children.</p>
<p><span class="Bold">What should I tell my doctor before receiving Beleodaq?</span></p>
<p><span class="Bold">Before receiving Beleodaq, tell your doctor about all of your medical conditions, including if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
<dt>â€¢</dt>
<dd>have had chemotherapy treatment</dd>
<dt>â€¢</dt>
<dd>have liver or kidney problems</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. Beleodaq can harm your unborn baby. You should not become pregnant while receiving Beleodaq. Tell your doctor right away if you become pregnant while receiving Beleodaq.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if Beleodaq passes into your breast milk. You and your doctor should decide if you will receive Beleodaq or breastfeed. You should not do both. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How will I receive Beleodaq?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Beleodaq will be given to you by intravenous (IV) injection into your vein, usually over 30 minutes.</dd>
<dt>â€¢</dt>
<dd>Beleodaq is given one time a day on Days 1 through 5 of a 21-day cycle of treatment.</dd>
<dt>â€¢</dt>
<dd>You should have regular blood tests before and during your treatment with Beleodaq. </dd>
<dt>â€¢</dt>
<dd>Your doctor may change your dose of Beleodaq, change when you receive your treatment, or stop treatment if you have certain side effects while receiving Beleodaq.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of Beleodaq?</span></p>
<p><span class="Bold">Beleodaq may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Low blood cell counts.</span> Your doctor will do blood tests to check your blood counts during your treatment with Beleodaq.<dl>
<dt>o</dt>
<dd>
<span class="Bold">Low platelet counts </span>can cause unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> under your skin. </dd>
<dt>o</dt>
<dd>
<span class="Bold">Low red blood cell counts</span> may make you feel weak, tired, or you get tired easily, you look <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, or you feel <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>.</dd>
<dt>o</dt>
<dd>
<span class="Bold">Low white blood cell counts </span>can cause you to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, which may be serious. </dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>People receiving Beleodaq may develop serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You may have a greater risk of life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> if you have had  chemotherapy in the past. Tell your doctor right away if you have any of the following signs or symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, burning with urination, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, or worsening skin problems. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Liver problems.</span> Beleodaq may cause liver problems which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your doctor will do blood tests during your treatment with Beleodaq to check for liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems: yellowing of the skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), dark urine, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the right upper stomach area.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> (TLS).</span> TLS is caused by a fast breakdown of cancer cells. Your doctor will check you for TLS during treatment with Beleodaq. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span> are common with Beleodaq and can sometimes be serious. Tell your doctor if you develop <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Your doctor may prescribe medicines to help prevent or treat these side effects.</dd>
</dl>
<p><span class="Bold">Common side effects of Beleodaq include </span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and low red blood cell count.</p>
<dl>
<dt>Â </dt>
<dd>Tell your doctor if you have any side effect that bothers you or that does not go away.</dd>
<dt>Â </dt>
<dd>These are not all the possible side effects of Beleodaq. Call your doctor for medical advice about side effects. You can report side effects to FDA at 1-800-FDA-1088.</dd>
</dl>
<p><span class="Bold">General information about Beleodaq</span></p>
<dl>
<dt>Â </dt>
<dd>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. YouÂ canÂ ask your pharmacist or doctor for information about Beleodaq that is written for health professionals.</dd>
</dl>
<p><span class="Bold">What are the ingredients in Beleodaq?</span></p>
<p>Active ingredient: belinostat<br>Inactive ingredients: L-Arginine </p>
<p>Manufactured for: Spectrum Pharmaceuticals, Inc. Irvine, CA 92618</p>
<p>Beleodaq is a registered trademark of Spectrum Pharmaceuticals, Inc. All rights reserved. </p>
<p>For more information, go to www.Beleodaq.com or call 1-888-292-9617.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.	Issued: July 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d54f1a13-ad9b-415f-ac53-ec00b656d096"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1793242951"></a><img alt="Carton, 500 mg / Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-02.jpg">
</div>
<div class="Figure">
<a name="id1793242952"></a><img alt="Vial, 500 mg / Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BELEODAQÂ 		
					</strong><br><span class="contentTableReg">belinostat injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68152-108</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BELINOSTAT</strong> (BELINOSTAT) </td>
<td class="formItem">BELINOSTAT</td>
<td class="formItem">500Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ARGININE</strong></td>
<td class="formItem">1000Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68152-108-09</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA206256</td>
<td class="formItem">07/21/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Spectrum Pharmaceuticals, Inc.
							(790888002)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d757b960-71d5-44a7-a490-744bd04e95ef</div>
<div>Set id: 84b2e16e-f0d1-4757-8da8-79dfa83aab79</div>
<div>Version: 2</div>
<div>Effective Time: 20140716</div>
</div>
</div>Â <div class="DistributorName">Spectrum Pharmaceuticals, Inc.</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BELEODAQ- belinostatÂ injection, powder, lyophilized, for solutionÂ </strong><br>Spectrum Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.<br><br>BELEODAQÂ® (belinostat) for injection, for intravenous administration<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Beleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. <span class="Italics"><a href="#i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f">(1)</a></span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Recommended dosage of Beleodaq is 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes by intravenous infusion once daily on days 1-5 of a 21-day cycle. Cycles can be repeated until disease progression or unacceptable toxicity. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac">2.1</a></span>)</dd>
<dt>â€¢</dt>
<dd>Treatment discontinuation or interruption with or without dosage reductions by 25% may be needed to manage adverse reactions. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a></span>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">For injection: 500 mg, lyophilized powder in single-use vial for reconstitution (<span class="Italics"><a href="#i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282">3</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<span class="Italics"><a href="#i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8">4</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>: Monitor blood counts and modify dosage for hematologic toxicities. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>, <a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a></span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>: Serious and fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>). (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a></span>)</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities. Monitor liver function tests and omit or modify dosage for hepatic toxicities. (<span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>, <a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a></span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span>: Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions. (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</a></span>)</dd>
<dt>â€¢</dt>
<dd>Embryo-fetal toxicity: Beleodaq may cause fetal harm when administered to a pregnant woman. Advise women of potential harm to the fetus and to avoid pregnancy while receiving Beleodaq. (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a></span>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;25%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<span class="Italics"><a href="#i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0">6</a></span>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Spectrum Pharmaceuticals, Inc. at 1-888-292-9617 or FDA at 1-800-FDA-1088</span>Â <span class="Bold">or</span>Â <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Italics">Nursing Mothers: </span> Women should be advised against breastfeeding while being treated with Beleodaq. (<span class="Italics"><a href="#i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574">8.3</a></span>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Modification for Hematologic and Non-Hematologic Toxicities</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with Reduced UGT1A1 Activity</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation and Administration Precautions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Reconstitution and Infusion Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hematologic Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 UGT1A1 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Warfarin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_bd85e0b4-7d04-48a7-afd1-b6b75e05a93f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Beleodaq is indicated for the treatment of patients with relapsed or refractory peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (PTCL).</p>
<p>This indication is approved under accelerated approval based on tumor response rate and duration of response <span class="Italics">[see Clinical Studies (<a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a>)].</span> An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_705dc3e0-5643-4404-b535-9194181538ac"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended dosage of Beleodaq is 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes by intravenous infusion once daily on Days 1-5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or unacceptable toxicity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Modification for Hematologic and Non-Hematologic Toxicities</h2>
<p class="First">Table 1 displays the recommended Beleodaq dosage modifications for hematologic and non-hematologic toxicities. Base dosage adjustments for <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> on platelet and absolute neutrophil nadir (lowest value) counts in the preceding cycle of therapy.</p>
<dl>
<dt>â€¢</dt>
<dd>Absolute neutrophil count (ANC) should be greater than or equal to 1.0 x 10<span class="Sup">9</span>/L and the platelet count should be greater than or equal to 50 x 10<span class="Sup">9</span>/L prior to the start of each cycle and prior to resuming treatment following toxicity. Resume subsequent treatment with Beleodaq according to the guidelines described in Table 1 below. Discontinue Beleodaq in patients who have recurrent ANC nadirs less than 0.5 x 10<span class="Sup">9</span>/L and/or recurrent platelet count nadirs less than 25 x 10<span class="Sup">9</span>/L after two dosage reductions.</dd>
<dt>â€¢</dt>
<dd>Other toxicities must be NCI-CTCAE Grade 2 or less prior to re-treatment.</dd>
</dl>
<p>Monitor complete blood counts at baseline and weekly. Perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle. </p>
<table width="100%">
<caption><span>Table 1: Dosage Modifications for Hematologic and Non-Hematologic Toxicities</span></caption>
<col width="56%">
<col width="44%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>For <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, only dose modify if the duration is greater than 7 days with supportive management</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dosage Modification</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First"><span class="Bold">Dosage Modifications due to Hematologic Toxicities</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Platelet count â‰¥ 25 x 10<span class="Sup">9</span>/L and nadir ANC â‰¥ 0.5 x 10<span class="Sup">9</span>/L</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">No Change</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Nadir ANC &lt; 0.5 x 10<span class="Sup">9</span>/L (any platelet count)</p></td>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="First">Decrease dosage by 25% (750 mg/m<span class="Sup">2</span>)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Platelet count &lt; 25 x 10<span class="Sup">9</span>/L (any nadir ANC)</p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="middle"><p class="First"><span class="Bold">Dosage Modifications due to Non-Hematologic Toxicities</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Any CTCAE Grade 3 or 4 adverse reaction<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Decrease dosage by 25% (750 mg/m<span class="Sup">2</span>)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Â Â Â Recurrence of CTCAE Grade 3 or 4 adverse reaction after two dosage reductions</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Discontinue Beleodaq</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_66ef38bd-654c-425e-8932-5a423a723d2f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with Reduced UGT1A1 Activity</h2>
<p class="First">Reduce the starting dose of Beleodaq to 750 mg/m<span class="Sup">2</span> in patients known to be homozygous for the UGT1A1*28 allele <span class="Italics">[see Clinical Pharmacology (<a href="#ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c">12.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_9a204218-9064-4333-9d6d-52c5b5836041"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation and Administration Precautions</h2>
<p class="First">As with other potentially cytotoxic anticancer agents, exercise care in the handling and preparation of solutions prepared with Beleodaq.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_509787c6-fc67-4d60-851e-574992f9a805"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Reconstitution and Infusion Instructions</h2>
<dl>
<dt>a)</dt>
<dd>Aseptically reconstitute each vial of Beleodaq by adding 9 mL of Sterile Water for injection, USP, into the Beleodaq vial with a suitable syringe to achieve a concentration of 50 mg of belinostat per mL. Swirl the contents of the vial until there are no visible particles in the resulting solution. The reconstituted product may be stored for up to 12 hours at ambient temperature (15-25Â°C; 59-77Â°F).</dd>
<dt>b)</dt>
<dd>Aseptically withdraw the volume needed for the required dosage (based on the 50 mg/mL concentration and the patientâ€™s BSA [m<span class="Sup">2</span>]) and transfer to an infusion bag containing 250 mL of 0.9 % Sodium Chloride injection. The infusion bag with drug solution may be stored at ambient room temperature (15-25Â°C; 59-77Â°F) for up to 36 hours including infusion time.</dd>
<dt>c)</dt>
<dd>Visually inspect the solution for particulate matter. Do not use if cloudiness or particulates are observed.</dd>
<dt>d)</dt>
<dd>Connect the infusion bag containing drug solution to an infusion set with a 0.22 Âµm in-line filter for administration.</dd>
<dt>e)</dt>
<dd>Infuse intravenously over 30 minutes. If infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or other symptoms potentially attributable to the infusion occur, the infusion time may be extended to 45 minutes.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_1ce8ead3-5c3f-4322-baf7-ac7f17238282"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">For injection: 500 mg, lyophilized powder in single-use vial for reconstitution</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_70cd9c3e-3bce-43de-920d-85b4f3d238b8"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_4f5d1822-ea0a-4087-8d1a-b3de996531f7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hematologic Toxicity</h2>
<p class="First">Beleodaq can cause <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; monitor blood counts weekly during treatment, and modify dosage as necessaryÂ <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a></span>) and <span class="Italics">Adverse Reactions</span><span class="Italics">(<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, have occurred with Beleodaq. Do not administer Beleodaq to patients with an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients with a history of extensive or intensive chemotherapy may be at higher risk of life threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatotoxicity</h2>
<p class="First">Beleodaq can cause fatal hepatotoxicity and liver function test abnormalitiesÂ <span class="Italics">[see Adverse Reactions</span> (<span class="Italics"><a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue Beleodaq based on the severity of the hepatic toxicity<span class="Italics">[see Dosage and Administration (</span><span class="Italics"><a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> has occurred in Beleodaq-treated patients in the clinical trial of patients with relapsed or refractory PTCLÂ <span class="Italics">[see</span>Â <span class="Italics">Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>. Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautionsÂ <span class="Italics">[see</span>Â <span class="Italics">Adverse Reactions</span> (<span class="Italics"><a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a></span>)<span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur with BeleodaqÂ <span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)] </span>and may require the use of antiemetic and antidiarrheal medications.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Embryo-fetal Toxicity</h2>
<p class="First">Beleodaq can cause fetal harm when administered to a pregnant woman. Beleodaq may cause <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cellsÂ <span class="Italics">[see Nonclinical Toxicology</span> (<span class="Italics"><a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</a></span>)<span class="Italics">]</span>. Women of childbearing potential should be advised to avoid pregnancy while receiving Beleodaq. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of potential hazard to the fetusÂ <span class="Italics">[see Use in Specific Populations</span> (<span class="Italics"><a href="#i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9">8.1</a></span>)<span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6682c765-3289-4603-bc0e-cca4270f40d0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described in more detail in other sections of the prescribing information.</p>
<dl>
<dt>â€¢</dt>
<dd>Hematologic ToxicityÂ <span class="Italics">[see Warnings and Precautions</span> (<span class="Italics"><a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span><span class="Italics"> [see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_668fce8b-e795-4108-ac04-7a968489e817">5.4</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</a>)]</span>
</dd>
</dl>
<p>The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Beleodaq may not reflect the rates observed in practice.</p>
<p><span class="Underline">Adverse Reactions in Patients with Peripheral T-Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<p>The safety of Beleodaq was evaluated in 129 patients with relapsed or refractory PTCL in the single arm clinical trial in which patients were administered Beleodaq at a dosage of 1,000 mg/m2 administered over 30 minutes by IV infusion once daily on Days 1-5 of a 21-day cycle <span class="Italics">[see Clinical Studies</span> (<span class="Italics"><a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a></span>)<span class="Italics">]</span>. The median duration of treatment was 2 cycles (range 1 â€“ 33 cycles).</p>
<p>Table 2 summarizes the adverse reactions regardless of causality from the trial in patients with relapsed or refractory PTCL.</p>
<table width="98.58%">
<caption><span>Table 2: Adverse Reactions Occurring in â‰¥ 10% of Patients by Preferred Term and Severity in Patients with Relapsed or Refractory PTCL (NCI-CTC Grade 1-4)</span></caption>
<col width="52%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">MedDRA Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle">
<p class="First"><span class="Bold">Percentage of Patients (%)</span></p>
<p><span class="Bold">(N=129)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">All Grades</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Grade 3 or 4</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">All Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">97</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">61</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Increased Blood Lactate Dehydrogenase </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Infusion Site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Prolonged QT </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Note: Adverse reactions are listed by order of incidence in the â€œAll Gradesâ€? category first, then by incidence in â€œthe Grade 3 or 4â€? category; MedDRA = Medical Dictionary for Regulatory Activities; Severity measured by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0</p>
<p><span class="Underline">Serious Adverse Reactions</span></p>
<p>Sixty-one patients (47.3%) experienced serious adverse reactions while taking Beleodaq or within 30 days after their last dose of Beleodaq. The most common serious adverse reactions (&gt; 2%) were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and multi-organ failure. One treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> was reported in the trial.</p>
<p>One patient with baseline <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and bulky disease experienced Grade 4 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> during the first cycle of treatment and died due to multi-organ failure. A treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> was reported in another monotherapy clinical trial with Beleodaq. ECG analysis did not identify QTc prolongation.</p>
<p><span class="Underline">Discontinuations due to Adverse Reactions</span></p>
<p>Twenty-five patients (19.4%) discontinued treatment with Beleodaq due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment included <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and multi-organ failure.</p>
<p><span class="Underline">Dosage Modifications due to Adverse Reactions</span></p>
<p>In the trial, dosage adjustments due to adverse reactions occurred in 12% of Beleodaq-treated patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_456775d3-18a0-4b58-8d34-377cd2f5e7ee"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_a497571b-109d-4617-847a-56cac2dfd851"></a><a name="section-7.1"></a><p></p>
<h2>7.1 UGT1A1 Inhibitors</h2>
<p class="First">Belinostat is primarily metabolized by UGT1A1. Avoid concomitant administration of Beleodaq with strong inhibitors of UGT1A1 <span class="Italics">[see Clinical Pharmacology</span> (<span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a></span>)<span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_e4ace375-7ddc-40c0-9140-3c4e47ae7fa7"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Warfarin</h2>
<p class="First">Co-administration of Beleodaq and warfarin resulted in no clinically relevant increase in plasma exposure of either R-warfarin or S-warfarin that would require a dose adjustment <span class="Italics">[see Clinical Pharmacology (</span><span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3)</a></span><span class="Italics">]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_27d12dca-1cef-4c30-a27b-2b3f309adcad"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d337985e-0aae-4e20-9c5c-6d836f82adc9"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a><a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">)</a></span>].</p>
<p><span class="Italics">Risk Summary</span></p>
<p>Beleodaq may cause <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and/or embryo-fetal lethality because it is a genotoxic drug and targets actively dividing cells <span class="Italics">[see Nonclinical Toxicology (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d">13.1</a>)]</span>. Women should avoid pregnancy while receiving Beleodaq. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of potential hazard to the fetus. </p>
<p><span class="Italics">Animal Data</span></p>
<p>No reproductive and developmental animal toxicology studies have been conducted with belinostat.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_595c7521-0902-432e-88d4-7fcfb5759574"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether belinostat is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Beleodaq, a decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fc875ec0-c1a4-4690-b737-865272ba9472"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pediatric patients were not included in clinical trials. The safety and effectiveness of Beleodaq in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_c27428be-56cb-4540-844a-37578fdfd2b2"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the single-arm trial, 48% of patients (n = 62) were â‰¥ 65 years of age and 10% of patients (n=13) were â‰¥ 75 years of age <span class="Italics">[see Clinical Studies (<a href="#i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8">14</a>)]</span>. The median age of the trial population was 63 years. Patients â‰¥ 65 years of age had a higher response rate to Beleodaq treatment than patients &lt; 65 years of age (36% versus 16%) while no meaningful differences in response rate were observed between patients â‰¥ 75 years of age and those &lt; 75 years of age. No clinically meaningful differences in serious adverse reactions were observed in patients based on age (&lt; 65 years compared with â‰¥ 65 years or &lt; 75 years of age compared with â‰¥ 75 years of age).</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_duplicate_id_8c25fb28-cfbd-489b-92f1-7a46d506ee2f"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Belinostat is metabolized in the liver and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is expected to increase exposure to belinostat. Patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt;1.5 x upper limit of normal (ULN)) were excluded from clinical trials. </p>
<p>There is insufficient data to recommend a dose of Beleodaq in patients with moderate and severe hepatic impairmentÂ <span class="Italics">[seeÂ Clinical PharmacologyÂ (<a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_duplicate_id_9f086d02-a930-4b85-ad93-77a6aeec7a23"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Approximately 40% of the belinostat dose is excreted renally, primarily as metabolites. Belinostat exposure is not altered in patients with Creatinine Clearance (CLcr) &gt; 39 mL/min. There is insufficient data to recommend a dose of Beleodaq in patients with CLcr â‰¤ 39 mL/min. <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_24dd5315-f21c-484c-9b2a-547f9f42ac9a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, general supportive measures should be instituted as deemed necessary by the treating physician. The elimination half-life of belinostat is 1.1 hoursÂ <span class="Italics">[see Clinical Pharmacology</span> (<span class="Italics"><a href="#i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c">12.3)</a></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d8e21c3f-5354-456b-901e-210f62270c6b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Beleodaq is a histone deacetylase inhibitor with a sulfonamide-hydroxamide structure. The chemical name of belinostat is (2E)-<span class="Italics">N</span>-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide. The structural formula is as follows:</p>
<div class="Figure">
<a name="id650"></a><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-01.jpg">
</div>
<p>The molecular formula is C<span class="Sub">15</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">4</span>S and the molecular weight is 318.35 g/mol.</p>
<p>Belinostat is a white to off-white powder. It is slightly soluble in distilled water (0.14 mg/mL) and polyethylene glycol 400 (about 1.5 mg/mL), and is freely soluble in ethanol (&gt; 200 mg/mL). The pKa values are 7.87 and 8.71 by potentiometry and 7.86 and 8.59 by UV.</p>
<p>Beleodaq (belinostat) for injection is supplied as a sterile lyophilized yellow powder containing 500 mg belinostat as the active ingredient. Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. The drug product is supplied in a single-use 30 mL clear glass vial with a coated stopper and aluminum crimp seal with â€œflip-offâ€? cap. Beleodaq is intended for intravenous administration after reconstitution with 9 mL Sterile Water for injection, and the reconstituted solution is further diluted with 250 mL of sterile 0.9% Sodium Chloride injection prior to infusion <span class="Italics">[see Dosage and Administration (</span><span class="Italics"><a href="#i4i_dosage_admin_id_cd52eefe-4b2b-4906-be62-5b36b0012476">2)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3db12f71-0cfd-48c9-a69f-ff934e1a006f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_8e6ba92d-e3d3-4963-939c-29b326bbd4b3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. <span class="Italics">In vitro</span>, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (&lt;250 nM).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9a3135c6-b8ac-4597-97ba-48523e9a274e"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Cardiac Electrophysiology</span></p>
<p>Multiple clinical trials have been conducted with Beleodaq, in many of which ECG data were collected and analyzed by a central laboratory. Analysis of clinical ECG and belinostat plasma concentration data demonstrated no meaningful effect of Beleodaq on cardiac repolarization. None of the trials showed any clinically relevant changes caused by Beleodaq on heart rate, PR duration or QRS duration as measures of autonomic state, atrio-ventricular conduction or depolarization; there were no cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d32f7061-acf2-4fb0-940f-79091b04bc8c"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic characteristics of belinostat were analyzed from pooled data from phase 1/2 clinical studies that used doses of belinostat ranging from 150 to 1200 mg/m<span class="Sup">2</span>. The total mean plasma clearance and elimination half-life were 1240 mL/min and 1.1 hours, respectively. The total clearance approximates average hepatic blood flow (1500 mL/min), suggesting high hepatic extraction (clearance being flow dependent).</p>
<p><span class="Underline">Distribution</span></p>
<p>The mean belinostat volume of distribution approaches total body water, indicating that belinostat has limited body tissue distribution. <span class="Italics">In vitro</span> plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Belinostat is primarily metabolized by hepatic UGT1A1. Strong UGT1A1 inhibitors are expected to increase exposure to belinostat. Belinostat also undergoes hepatic metabolism by CYP2A6, CYP2C9, and CYP3A4 enzymes to form belinostat amide and belinostat acid. The enzymes responsible for the formation of methyl belinostat and 3-(anilinosulfonyl)-benzenecarboxylic acid, (3-ASBA) are not known.</p>
<p><span class="Underline">Excretion</span></p>
<p>Belinostat is eliminated predominantly through metabolism with less than 2% of the dose recovered unchanged in urine. All major human metabolites (methyl belinostat, belinostat amide, belinostat acid, belinostat glucuronide, and 3-ASBA) are generally excreted in urine within the first 24 hours after dose administration. Metabolites 3-ASBA and belinostat glucuronide represented the highest fractions of the belinostat dose excreted in urine (4.61% and 30.5%, respectively).</p>
<p><span class="Underline">Drug-Drug Interactions</span></p>
<p>In vitro studies showed belinostat and its metabolites (including belinostat glucuronide, belinostat amide, methyl belinostat) inhibited metabolic activities of CYP2C8 and CYP2C9. Other metabolites (3-ASBA and belinostat acid) inhibited CYP2C8. </p>
<p>In cancer patients, co-administration of Beleodaq (1,000 mg/m<span class="Sup">2</span>) and warfarin (5 mg), a known CYP2C9 substrate, did not increase the AUC or C<span class="Sub">max</span> of either R- or S-warfarin. </p>
<p>Belinostat is likely a glycoprotein (P-gp) substrate but is unlikely to inhibit P-gp.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a1e83ce3-d2f4-495f-ada6-bf6ae6c5aa5c"></a><a name="section-11.4"></a><p></p>
<h2>12.5 Pharmacogenomics</h2>
<p class="First">UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 20% of the black population, 10% of the white population, and 2% of the Asian population are homozygous for the UGT1A1*28 allele. Additional reduced function alleles may be more prevalent in specific populations.</p>
<p>Because belinostat is primarily (80 -90%) metabolized by UGT1A1, the clearance of belinostat could be decreased in patients with reduced UGT1A1 activity (e.g., patients with UGT1A1*28 allele). Reduce the starting dose of Beleodaq to 750 mg/m<span class="Sup">2</span> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_2e570443-2e43-4d3d-a022-36529932ec42"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ae822a72-aa40-4bb7-a676-649b947cc75d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been performed with belinostat.</p>
<p>Belinostat was genotoxic in a bacterial reverse mutation test (Ames assay), an in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell mutagenesis assay, and an in vivo rat micronucleus assay. </p>
<p>Beleodaq may impair male fertility. Fertility studies using belinostat were not conducted. However, belinostat effects on male reproductive organs observed during the 24-week repeat-dose dog toxicology study included reduced organ weights of the testes/epididymides that correlated with a delay in testicular maturation</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_bda88c73-178c-4cca-9d7e-47a3b17651e8"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Underline">Relapsed or Refractory Peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (PTCL)</span></p>
<p>In an open-label, single-arm, non-randomized international trial conducted at 62 centers, 129Â patients with relapsed or refractory PTCL were treated with Beleodaq 1,000 mg/m<span class="Sup">2</span> administered over 30 minutes via IV infusion once daily on Days 1-5 of a 21-day cycle. There were 120 patients who had histologically confirmed PTCL by central review evaluable for efficacy. Patients were treated with repeat cycles every three weeks until disease progression or unacceptable toxicity.</p>
<p>The primary efficacy endpoint was response rate (complete response and partial response) as assessed by an independent review committee (IRC) using the International Workshop Criteria (IWC) (Cheson 2007). The key secondary efficacy endpoint was duration of response. Response assessments were evaluated every 6 weeks for the first 12 months and then every 12 weeks until 2 years from the start of study treatment. Duration of response was measured from the first day of documented response to disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Response and progression of disease were evaluated by the IRC using the IWC.</p>
<p>Table 3 summarizes the baseline demographic and disease characteristics of the study population, who were evaluable for efficacy.</p>
<a name="_RefID991E21B9E3224CD4AB1EBFB4881FA21E"></a><table width="100%">
<caption><span>Table 3 Baseline Patient Characteristics (PTCL Population)</span></caption>
<col width="70%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Characteristics</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Evaluable Patients</span></p>
<p><span class="Bold">(N=120)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Age (years)</p>
<dl>
<dt>Â </dt>
<dd>	Median (range)</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">64.0 (29-81)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Sex, %</p>
<dl>
<dt>Â </dt>
<dd>	Male</dd>
<dt>Â </dt>
<dd>	Female</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">52</p>
<p>48</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Race, %</p>
<dl>
<dt>Â </dt>
<dd>White</dd>
<dt>Â </dt>
<dd>Black</dd>
<dt>Â </dt>
<dd>Asian</dd>
<dt>Â </dt>
<dd>Latin</dd>
<dt>Â </dt>
<dd>Other</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">88</p>
<p>6</p>
<p>3</p>
<p>3</p>
<p>2</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">PTCL Subtype Based on Central Diagnosis, %</p>
<dl>
<dt>Â </dt>
<dd>	PTCL Unspecified (NOS)</dd>
<dt>Â </dt>
<dd>	Angioimmunoblastic T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (AITL)</dd>
<dt>Â </dt>
<dd>	ALK-1 negative anaplastic large cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (ALCL)</dd>
<dt>Â </dt>
<dd>	Other</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">64</p>
<p>18</p>
<p>11</p>
<p>7</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Baseline Platelet Count, %</p>
<dl>
<dt>Â </dt>
<dd>	â‰¥100,000/Î¼L</dd>
<dt>Â </dt>
<dd>	&lt;100,000/Î¼L</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">83</p>
<p>17</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">ECOG Performance Status, %</p>
<dl>
<dt>Â </dt>
<dd>	0</dd>
<dt>Â </dt>
<dd>	1</dd>
<dt>Â </dt>
<dd>	2</dd>
<dt>Â </dt>
<dd>3</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"></p>
<p>34</p>
<p>43</p>
<p>22</p>
<p>1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Median time (months) from Initial PTCL Diagnosis (Range)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12.0 (2.6 â€“ 266.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Median Number of Prior Systemic Therapies (Range)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2.0 (1-8)</p></td>
</tr>
</tbody>
</table>
<p>In all evaluable patients (N = 120) treated with Beleodaq, the overall response rate per central review using IWC was 25.8% (n = 31) (Table 4) with rates of 23.4% for PTCL, NOS and 45.5% for AITL, the two largest subtypes enrolled. </p>
<a name="_RefID6F802A4E4EF345BDB8C7891823F5598D"></a><table cellpadding="3pt" width="541.5pt">
<caption><span>Table 4: Response Analysis per Central Assessment Using IWC in Patients with Relapsed or Refractory PTCL</span></caption>
<col width="52%">
<col width="24%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Evaluable Patients<br>(N=120)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold"> Response Rate</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">n (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">(95% CI)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>CR+PR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31 (25.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18.3-34.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>CR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13 (10.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9-17.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>PR</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18 (15.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.1 â€“ 22.7</p></td>
</tr>
</tbody>
</table>
<p>CI=confidence interval, CR=complete response, PR=partial response</p>
<p>The median duration of response based on the first date of response to disease progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 8.4 months (95% CI: 4.5 â€“ 29.4). Of the responders, the median time to response was 5.6 weeks (range 4.3 - 50.4 weeks). Nine patients (7.5%) were able to proceed to a stem cell transplant after treatment with Beleodaq.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_60003015-7603-4806-bdf0-b0e4ba2e15cd"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>OSHA Hazardous Drugs. <span class="Italics">OSHA</span>. [Accessed on 14 May 2014, from <span class="Italics"><a href="http://www.osha.gov/SLTC/hazardousdrugs/index.html">http://www.osha.gov/SLTC/hazardousdrugs/index.html</a></span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5e08debb-9ee1-4da3-a2f7-7953e5276de4"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">16.1 How Supplied</span></p>
<p>Beleodaq (belinostat) for injection is supplied in single vial cartons; each 30 mL clear vial contains sterile, lyophilized powder equivalent to 500 mg belinostat.</p>
<p>NDC 68152-108-09<span class="Bold">: </span>Individual carton of Beleodaq 30 mL single-use vial containing 500 mg belinostat.</p>
<p><span class="Bold">16.2 Storage and Handling</span></p>
<p>Store Beleodaq (belinostat) for injection at room temperature 20Â°C  to 25Â°C (68Â°C  to 77Â°F). Excursions are permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F). Retain in original package until use. [see USP Controlled Room Temperature]. </p>
<p>Beleodaq is a cytotoxic drug. Follow special handling and disposal procedures <span class="Italics">[see References (<a href="#i4i_references_id_60003015-7603-4806-bdf0-b0e4ba2e15cd">15</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_9fb597bb-e1a3-4e33-ab47-f9285b5029f2"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians should discuss the FDA approved Patient Information Leaflet with patients prior to treatment with Beleodaq. Instruct patients to read the Patient Information Leaflet carefully.</p>
<p>Advise the patient or the caregiver to read the FDA-approved patient labeling (Patient Information).</p>
<p>Advise patients or their caregivers:</p>
<dl>
<dt>â€¢</dt>
<dd>To report symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> so that appropriate antiemetic and antidiarrheal medications can be administered <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_49dcd61c-eba6-470e-81b4-22906eedf8a5">5.5</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>To report any symptoms of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see Warnings and Precautions (</span><a href="#i4i_warnings_precautions_duplicate_id_a04155ea-6f95-47e5-8c09-367ea803db64">5.1</a><span class="Italics">)]</span>.</dd>
<dt>â€¢</dt>
<dd>To immediately report symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>) <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_d0b6251e-44fb-4858-8ec1-4a3fe5baeb85">5.2</a>) </span>and<span class="Italics"> Adverse Reactions (<a href="#i4i_adverse_effects_duplicate_id_5c504009-dda4-497e-aaeb-0569803afd41">6.1</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>Of the potential risk to the fetus and for women to avoid pregnancy while receiving Beleodaq <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_4b109ea0-c693-426c-9cf7-ec6f2064bfa6">5.6</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>To understand the importance of monitoring liver function test abnormalities and to immediately report potential symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_duplicate_id_d8270f47-029c-415a-8456-dd8c03ddeacb">2.2</a>) </span>and<span class="Italics"> Warnings and Precautions (<a href="#i4i_warnings_precautions_duplicate_id_9ade663d-ebf2-4d6d-b235-591854fb2131">5.3</a>)].</span>
</dd>
</dl>
<p>Manufactured for: </p>
<p>Spectrum Pharmaceuticals, Inc.</p>
<p>Irvine, CA 92618</p>
<p>Beleodaq is a registered trademark of Spectrum Pharmaceuticals, Inc. All rights are reserved.</p>
<p>U.S. Patent: 6,888,027</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_87ad9416-0663-4f1b-80c3-ff7b2368b135"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">BELEODAQ<span class="Sup">Â®</span></span>(BÄ“-lÄ“o-dak)</p>
<p>(belinostat) for injection, for intravenous use</p>
<p>Read this Patient Information before you receive treatment with Beleodaq and each time you receive Beleodaq. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is Beleodaq?</span></p>
<p>Beleodaq is a prescription medicine used to treat people with a type of cancer called peripheral T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (PTCL) that comes back or does not respond to cancer treatment. </p>
<p>It is not known if Beleodaq is safe and effective in children.</p>
<p><span class="Bold">What should I tell my doctor before receiving Beleodaq?</span></p>
<p><span class="Bold">Before receiving Beleodaq, tell your doctor about all of your medical conditions, including if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
<dt>â€¢</dt>
<dd>have had chemotherapy treatment</dd>
<dt>â€¢</dt>
<dd>have liver or kidney problems</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. Beleodaq can harm your unborn baby. You should not become pregnant while receiving Beleodaq. Tell your doctor right away if you become pregnant while receiving Beleodaq.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if Beleodaq passes into your breast milk. You and your doctor should decide if you will receive Beleodaq or breastfeed. You should not do both. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How will I receive Beleodaq?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Beleodaq will be given to you by intravenous (IV) injection into your vein, usually over 30 minutes.</dd>
<dt>â€¢</dt>
<dd>Beleodaq is given one time a day on Days 1 through 5 of a 21-day cycle of treatment.</dd>
<dt>â€¢</dt>
<dd>You should have regular blood tests before and during your treatment with Beleodaq. </dd>
<dt>â€¢</dt>
<dd>Your doctor may change your dose of Beleodaq, change when you receive your treatment, or stop treatment if you have certain side effects while receiving Beleodaq.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of Beleodaq?</span></p>
<p><span class="Bold">Beleodaq may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Low blood cell counts.</span> Your doctor will do blood tests to check your blood counts during your treatment with Beleodaq.<dl>
<dt>o</dt>
<dd>
<span class="Bold">Low platelet counts </span>can cause unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> under your skin. </dd>
<dt>o</dt>
<dd>
<span class="Bold">Low red blood cell counts</span> may make you feel weak, tired, or you get tired easily, you look <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, or you feel <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>.</dd>
<dt>o</dt>
<dd>
<span class="Bold">Low white blood cell counts </span>can cause you to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, which may be serious. </dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </span>People receiving Beleodaq may develop serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You may have a greater risk of life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> if you have had  chemotherapy in the past. Tell your doctor right away if you have any of the following signs or symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, burning with urination, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, or worsening skin problems. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Liver problems.</span> Beleodaq may cause liver problems which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your doctor will do blood tests during your treatment with Beleodaq to check for liver problems. Tell your doctor right away if you have any of the following signs or symptoms of liver problems: yellowing of the skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), dark urine, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the right upper stomach area.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> (TLS).</span> TLS is caused by a fast breakdown of cancer cells. Your doctor will check you for TLS during treatment with Beleodaq. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span> are common with Beleodaq and can sometimes be serious. Tell your doctor if you develop <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Your doctor may prescribe medicines to help prevent or treat these side effects.</dd>
</dl>
<p><span class="Bold">Common side effects of Beleodaq include </span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and low red blood cell count.</p>
<dl>
<dt>Â </dt>
<dd>Tell your doctor if you have any side effect that bothers you or that does not go away.</dd>
<dt>Â </dt>
<dd>These are not all the possible side effects of Beleodaq. Call your doctor for medical advice about side effects. You can report side effects to FDA at 1-800-FDA-1088.</dd>
</dl>
<p><span class="Bold">General information about Beleodaq</span></p>
<dl>
<dt>Â </dt>
<dd>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. YouÂ canÂ ask your pharmacist or doctor for information about Beleodaq that is written for health professionals.</dd>
</dl>
<p><span class="Bold">What are the ingredients in Beleodaq?</span></p>
<p>Active ingredient: belinostat<br>Inactive ingredients: L-Arginine </p>
<p>Manufactured for: Spectrum Pharmaceuticals, Inc. Irvine, CA 92618</p>
<p>Beleodaq is a registered trademark of Spectrum Pharmaceuticals, Inc. All rights reserved. </p>
<p>For more information, go to www.Beleodaq.com or call 1-888-292-9617.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.	Issued: July 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d54f1a13-ad9b-415f-ac53-ec00b656d096"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1793242951"></a><img alt="Carton, 500 mg / Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-02.jpg">
</div>
<div class="Figure">
<a name="id1793242952"></a><img alt="Vial, 500 mg / Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=84b2e16e-f0d1-4757-8da8-79dfa83aab79&amp;name=61cb5fe6-0a97-4950-a706-d15031f008f0-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BELEODAQÂ 		
					</strong><br><span class="contentTableReg">belinostat injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68152-108</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BELINOSTAT</strong> (BELINOSTAT) </td>
<td class="formItem">BELINOSTAT</td>
<td class="formItem">500Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ARGININE</strong></td>
<td class="formItem">1000Â mg Â inÂ 10Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68152-108-09</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA206256</td>
<td class="formItem">07/21/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Spectrum Pharmaceuticals, Inc.
							(790888002)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d757b960-71d5-44a7-a490-744bd04e95ef</div>
<div>Set id: 84b2e16e-f0d1-4757-8da8-79dfa83aab79</div>
<div>Version: 2</div>
<div>Effective Time: 20140716</div>
</div>
</div>Â <div class="DistributorName">Spectrum Pharmaceuticals, Inc.</div></p>
</body></html>
